Applications of Liquid Biopsy Webinar Series – Colorectal Cancer

Register now

This webinar aims to review and discuss data for liquid biopsy-based assessments as endpoints of antitumour activity in clinical trials, understand the potential and limitations of liquid biopsy-based tumour genomic profiling for patient stratification and detection of predictive biomarkers of response to therapy, and to discuss how tumour heterogeneity and evolution assessed via liquid biopsy assays may improve colorectal cancer treatment strategies.

The webinar will also offer the opportunity for real-time interaction between audience and experts.

Chair

Clara Montagut

Speakers

Jeanne Tie, Andrea Sartore-Bianchi

Programme

• Welcome and Introduction, Prof. Clara Montagut, Gastrointestinal Cancer Unit, Medical Oncology, Hospital del Mar, Barcelona, Spain  
• ctDNA in Early-Stage Colorectal Cancer: MRD and Molecular Relapse Monitoring, Prof. Jeanne Tie, Department of Medical Oncology, Peter MacCallum Cancer Centre; Division of Personalised Oncology, Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia
• ctDNA for Advanced Cancer Genotyping and Evaluation of Tumour Response, Prof. Clara Montagut, Gastrointestinal Cancer Unit, Medical Oncology, Hospital del Mar, Barcelona, Spain  
• ctDNA to Capture Tumour Evolution and Drug Resistance Biomarkers, Prof. Andrea Sartore-Bianchi, Department of Oncology and Hematology-Oncology - University of Milano; Niguarda Cancer Center - Grande Ospedale Metropolitano Niguarda, Milan, Italy  
• Q&A
• Closing Remarks, Prof. Clara Montagut, Gastrointestinal Cancer Unit, Medical Oncology, Hospital del Mar, Barcelona, Spain  

Learning objectives

• Understand the concept and potential clinical applications of ctDNA in early-stage colorectal cancer in terms of detection of minimal residual disease and molecular relapse monitoring
• Understand the concept and potential clinical applications of ctDNA for advanced cancer genotyping and evaluation of tumour response
• Understand the concept and potential clinical applications of ctDNA to capture tumour evolution and drug resistance biomarkers